Abstract
Effective dose estimations have been carried out for some newer technetium-99 m labelled diagnostic agents employed for myocardial and regional cerebral perfusion studies. Mean absorbed doses due to these preparations were taken from published literature. Effective dose was calculated by multiplying mean absorbed dose to an organ or tissue by the value of tissue weighting factor assigned to that organ or tissue in the recommendations of the International Commission on Radiological Protection and integrating over all the organs or tissues of interest. The process was repeated considering the revised values of tissue weighting factors as recommended recently. A method for approximate effective dose calculation is described in cases where complete data on mean absorbed dose or tissue weighting factor for an organ or tissue are not available. The revised values of tissue weighting factor normally result in a lowering of estimated effective doses due to these radiopharmaceuticals. It has also been demonstrated that the additional total stochastic risk caused due to these nuclear medicine investigations will only be marginal.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
